About Corbus Pharmaceuticals (NASDAQ:CRBP)
Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases. The company's lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug that is in Phase III clinical trials for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. Corbus Pharmaceuticals Holdings, Inc. was founded in 2009 and is based in Norwood, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100
Debt
Debt-to-Equity RatioN/A
Current Ratio7.99%
Quick Ratio7.99%
Price-To-Earnings
Trailing P/E Ratio-10.23
Forward P/E Ratio-8.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.44 million
Price / Sales155.73
Cash FlowN/A
Price / CashN/A
Book Value$1.04 per share
Price / Book6.39
Profitability
EPS (Most Recent Fiscal Year)($0.65)
Net Income$-32,420,000.00
Net Margins-1,040.41%
Return on Equity-75.88%
Return on Assets-64.67%
Miscellaneous
Employees47
Outstanding Shares57,140,000
Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions
What is Corbus Pharmaceuticals' stock symbol?
Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
How were Corbus Pharmaceuticals' earnings last quarter?
Corbus Pharmaceuticals (NASDAQ:CRBP) announced its earnings results on Monday, March, 12th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.05. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 75.88%. View Corbus Pharmaceuticals' Earnings History.
What price target have analysts set for CRBP?
3 analysts have issued twelve-month price objectives for Corbus Pharmaceuticals' stock. Their predictions range from $20.00 to $32.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $25.3333 in the next twelve months. View Analyst Ratings for Corbus Pharmaceuticals.
Who are some of Corbus Pharmaceuticals' key competitors?
Some companies that are related to Corbus Pharmaceuticals include Adamas Pharmaceuticals (ADMS), NuCana (NCNA), GlycoMimetics (GLYC), Vanda Pharmaceuticals (VNDA), Karyopharm Therapeutics (KPTI), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), BeyondSpring (BYSI), Rocket Pharmaceuticals (RCKT), Omeros (OMER), AMAG Pharmaceuticals (AMAG), Endocyte (ECYT), Lannett (LCI), Reata Pharmaceuticals (RETA), Dicerna Pharmaceuticals (DRNA), Ziopharm Oncology (ZIOP), Geron (GERN) and Rhythm Pharmaceuticals (RYTM).
Who are Corbus Pharmaceuticals' key executives?
Corbus Pharmaceuticals' management team includes the folowing people:
- Dr. Yuval Cohen, CEO & Director (Age 43)
- Dr. Mark A. Tepper Ph.D., Co-Founder, Pres & Chief Scientific Officer (Age 61)
- Dr. Barbara White M.D., Chief Medical Officer (Age 68)
- Mr. Sean F. Moran CPA, MBA, CFO & Principal Accounting Officer (Age 60)
- Scott Constantine M.S., Director of Clinical Research & Operations
Has Corbus Pharmaceuticals been receiving favorable news coverage?
Headlines about CRBP stock have been trending somewhat positive on Sunday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Corbus Pharmaceuticals earned a news sentiment score of 0.07 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.49 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Corbus Pharmaceuticals?
Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corbus Pharmaceuticals' stock price today?
One share of CRBP stock can currently be purchased for approximately $6.65.
How big of a company is Corbus Pharmaceuticals?
Corbus Pharmaceuticals has a market capitalization of $379.98 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.
How can I contact Corbus Pharmaceuticals?
Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]
MarketBeat Community Rating for Corbus Pharmaceuticals (CRBP)
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Corbus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $25.3333, suggesting that the stock has a possible upside of 280.95%. The high price target for CRBP is $32.00 and the low price target for CRBP is $20.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.3333 | $25.75 | $24.75 | $19.75 |
| Price Target Upside: | 280.95% upside | 278.68% upside | 211.32% upside | 178.17% upside |
Corbus Pharmaceuticals (NASDAQ:CRBP) Consensus Price Target History
Corbus Pharmaceuticals (NASDAQ:CRBP) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Corbus Pharmaceuticals (NASDAQ:CRBP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Corbus Pharmaceuticals (NASDAQ CRBP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.90%
Institutional Ownership Percentage: 37.01%
Corbus Pharmaceuticals (NASDAQ CRBP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/14/2018 | Barbara White | Insider | Buy | 2,885 | $6.89 | $19,877.65 | 176,935 |  |
| 3/14/2018 | David P Hochman | Director | Buy | 5,000 | $6.67 | $33,350.00 | 459,500 | |
| 3/14/2018 | Sean F Moran | CFO | Buy | 3,100 | $6.60 | $20,460.00 | 344,010 | |
| 3/14/2018 | Yuval Cohen | CEO | Buy | 1,160 | $6.89 | $7,992.40 | 59,935 | |
| 11/15/2017 | David P Hochman | Director | Buy | 5,000 | $6.55 | $32,750.00 | 459,500 | |
| 11/13/2017 | David P Hochman | Director | Buy | 5,000 | $6.90 | $34,500.00 | | |
| 11/10/2017 | Barbara White | Insider | Buy | 2,836 | $7.00 | $19,852.00 | 174,050 | |
| 11/10/2017 | David P Hochman | Director | Buy | 10,000 | $7.08 | $70,800.00 | 459,500 | |
| 11/10/2017 | Sean F Moran | CFO | Buy | 1,500 | $7.04 | $10,560.00 | 340,910 | |
| 11/10/2017 | Yuval Cohen | CEO | Buy | 1,000 | $7.17 | $7,170.00 | 58,775 | |
| 8/11/2017 | Barbara White | Insider | Buy | 2,479 | $6.05 | $14,997.95 | 171,214 | |
| 8/11/2017 | Sean F Moran | CFO | Buy | 2,500 | $5.91 | $14,775.00 | 339,410 | |
| 8/11/2017 | Yuval Cohen | CEO | Buy | 1,695 | $6.00 | $10,170.00 | 57,775 | |
| 5/11/2017 | Barbara White | Insider | Buy | 2,435 | $6.12 | $14,902.20 | 168,735 | |
| 5/11/2017 | David P Hochman | Director | Buy | 3,400 | $6.18 | $21,012.00 | 459,500 | |
| 5/11/2017 | Sean F Moran | CFO | Buy | 3,300 | $6.14 | $20,262.00 | 336,910 | |
| 5/11/2017 | Yuval Cohen | CEO | Buy | 3,250 | $6.01 | $19,532.50 | 56,080 | |
| 3/17/2017 | Barbara White | Insider | Buy | 4,233 | $9.49 | $40,171.17 | 166,300 | |
| 3/13/2017 | Sean F Moran | CFO | Buy | 2,000 | $9.60 | $19,200.00 | 333,610 | |
| 12/2/2016 | Sean F Moran | CFO | Buy | 1,500 | $7.20 | $10,800.00 | 331,610 | |
| 11/22/2016 | Alan F Holmer | Director | Buy | 1,000 | $7.49 | $7,490.00 | 22,000 | |
| 11/22/2016 | Yuval Cohen | CEO | Buy | 1,340 | $7.64 | $10,237.60 | 12,830 | |
| 11/18/2016 | David P Hochman | Director | Buy | 10,000 | $7.00 | $70,000.00 | 456,100 | |
| 9/8/2016 | Sean F Moran | CFO | Buy | 30,800 | $5.12 | $157,696.00 | 330,110 | |
| 8/26/2016 | Sean F Moran | CFO | Buy | 17,900 | $3.92 | $70,168.00 | 299,310 | |
| 8/22/2016 | David P Hochman | Director | Buy | 1,800 | $3.77 | $6,786.00 | 456,100 | |
| 8/18/2016 | Sean F Moran | CFO | Buy | 148,960 | $3.32 | $494,547.20 | 216,410 | |
| 8/17/2016 | Barbara White | Insider | Buy | 38,000 | $3.15 | $119,700.00 | 161,067 | |
| 6/8/2016 | Barbara White | Insider | Buy | 1,935 | $3.10 | $5,998.50 | 123,067 | |
| 6/6/2016 | Yuval Cohen | CEO | Buy | 1,500 | $3.34 | $5,010.00 | 11,490 | |
| 6/1/2016 | Barbara White | Insider | Buy | 2,570 | $3.52 | $9,046.40 | 121,132 | |
| 5/19/2016 | Sean F Moran | CFO | Buy | 27,250 | $2.37 | $64,582.50 | 132,450 | |
| 5/18/2016 | Sean F Moran | CFO | Buy | 30,000 | $2.39 | $71,700.00 | 105,250 | |
| 5/18/2016 | Yuval Cohen | CEO | Buy | 2,125 | $2.40 | $5,100.00 | 9,990 | |
| 12/11/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.56 | $1,560.00 | 75,250 | |
| 12/10/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.61 | $1,610.00 | 74,250 | |
| 12/9/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.67 | $1,670.00 | 73,250 | |
| 12/8/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.68 | $1,680.00 | 72,250 | |
| 12/7/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.69 | $1,690.00 | 71,250 | |
| 12/4/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.72 | $1,720.00 | 70,250 | |
| 12/2/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.79 | $1,790.00 | 69,250 | |
| 11/24/2015 | Sean F Moran | CFO | Buy | 1,500 | $1.78 | $2,670.00 | 68,250 | |
| 11/20/2015 | Sean F Moran | CFO | Buy | 1,500 | $1.70 | $2,550.00 | 66,750 | |
| 11/19/2015 | Barbara White | Insider | Buy | 4,000 | $1.67 | $6,680.00 | 118,562 | |
| 11/18/2015 | Sean F Moran | CFO | Buy | 1,500 | $1.71 | $2,565.00 | 65,250 | |
| 11/17/2015 | Sean F Moran | CFO | Buy | 1,500 | $1.72 | $2,580.00 | 63,750 | |
| 11/16/2015 | Sean F Moran | CFO | Buy | 2,000 | $1.69 | $3,380.00 | 62,250 | |
| 9/16/2015 | Sean F Moran | CFO | Buy | 5,000 | $2.12 | $10,600.00 | 60,250 | |
| 9/15/2015 | Sean F Moran | CFO | Buy | 5,000 | $2.14 | $10,700.00 | 55,250 | |
| 9/14/2015 | Sean F Moran | CFO | Buy | 5,000 | $1.96 | $9,800.00 | 50,250 | |
| 9/11/2015 | Sean F Moran | CFO | Buy | 5,000 | $1.85 | $9,250.00 | 45,250 | |
| 9/3/2015 | Barbara White | Insider | Buy | 10,000 | $1.84 | $18,400.00 | 113,862 | |
| 8/25/2015 | Barbara White | Insider | Buy | 6,000 | $1.87 | $11,220.00 | 103,862 | |
| 8/21/2015 | Barbara White | Insider | Buy | 10,000 | $2.05 | $20,500.00 | 97,862 | |
| 8/21/2015 | Sean F Moran | CFO | Buy | 1,400 | $2.06 | $2,884.00 | 40,250 | |
| 8/19/2015 | Sumner Burstein | Major Shareholder | Sell | 200,000 | $3.04 | $608,000.00 | 3,594,846 | |
| 8/18/2015 | Barbara White | insider | Buy | 20,000 | $1.90 | $38,000.00 | 87,862 | |
| 8/18/2015 | Renu Gupta | Director | Buy | 10,000 | $1.89 | $18,900.00 | 15,000 | |
| 8/18/2015 | Sean F Moran | CFO | Buy | 1,000 | $1.92 | $1,920.00 | 38,850 | |
| 8/17/2015 | Avery W Catlin | Director | Buy | 11,788 | $1.94 | $22,868.72 | | |
| 8/17/2015 | Yuval Cohen | CEO | Buy | 2,100 | $1.92 | $4,032.00 | | |
| 7/15/2015 | Sumner Burstein | Major Shareholder | Sell | 30,000 | $2.82 | $84,600.00 | | |
| 6/15/2015 | Barbara White | Insider | Buy | 2,250 | $3.25 | $7,312.50 | | |
| 6/12/2015 | Barbara White | Insider | Buy | 6,000 | $3.00 | $18,000.00 | | |
| 6/9/2015 | Avery W Catlin | Director | Buy | 20,000 | $3.10 | $62,000.00 | | |
| 6/9/2015 | Sean F Moran | CFO | Buy | 6,500 | $3.00 | $19,500.00 | | |
| 12/18/2014 | Sean F Moran | CFO | Buy | 18,800 | $3.36 | $63,168.00 | | |
| 12/17/2014 | Sean F Moran | CFO | Buy | 2,850 | $3.46 | $9,861.00 | | |
| 12/11/2014 | Sean F Moran | CFO | Buy | 1,000 | $3.98 | $3,980.00 | | |
| 12/9/2014 | Sean F Moran | CFO | Buy | 1,700 | $3.98 | $6,766.00 | | |
| 12/4/2014 | Barbara White | Insider | Buy | 3,300 | $3.00 | $9,900.00 | | |
| 12/4/2014 | David P Hochman | Director | Buy | 1,300 | $3.05 | $3,965.00 | | |
| 12/4/2014 | Sean F Moran | CFO | Buy | 2,000 | $3.20 | $6,400.00 | | |
| 12/3/2014 | Yuval Cohen | CEO | Buy | 1,000 | $3.20 | $3,200.00 | | |
| 12/2/2014 | Sean F Moran | CFO | Buy | 1,000 | $3.03 | $3,030.00 | | |
| 12/1/2014 | Barbara White | Insider | Buy | 16,448 | $3.00 | $49,344.00 | | |
| 11/28/2014 | Barbara White | Insider | Buy | 19,933 | $3.00 | $59,799.00 | | |
| 11/26/2014 | Barbara White | Insider | Buy | 13,400 | $3.00 | $40,200.00 | | |
| 11/26/2014 | Sean F Moran | CFO | Buy | 1,000 | $3.05 | $3,050.00 | | |
| 11/25/2014 | Mark Tepper | Insider | Buy | 2,000 | $3.05 | $6,100.00 | | |
| 11/25/2014 | Sean F Moran | CFO | Buy | 3,000 | $3.05 | $9,150.00 | | |
(Data available from 1/1/2013 forward)
Corbus Pharmaceuticals (NASDAQ CRBP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | 3 Most Heavily Shorted Marijuana Stocks -- Are the Naysayers Wrong?
finance.yahoo.com - April 1 at 10:17 AM |
 | Corbus Pharmaceuticals (CRBP) PT Raised to $20.00
www.americanbankingnews.com - April 1 at 9:40 AM |
| TESARO (TSRO) and Corbus Pharmaceuticals (CRBP) Financial Review
www.americanbankingnews.com - March 19 at 2:08 PM |
| Corbus Pharmaceuticals (CRBP) Given a $32.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - March 18 at 12:27 PM |
| Corbus Pharmaceuticals (CRBP) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 17 at 6:44 PM |
| FY2018 EPS Estimates for Corbus Pharmaceuticals Holdings Inc Cut by Cantor Fitzgerald (CRBP)
www.americanbankingnews.com - March 16 at 10:48 AM |
 | Corbus Pharmaceuticals (CRBP) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 3:55 PM |
| Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Barbara White Buys 2,885 Shares
www.americanbankingnews.com - March 15 at 1:20 PM |
| Insider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Director Acquires 5,000 Shares of Stock
www.americanbankingnews.com - March 15 at 1:20 PM |
| Noble Financial Reaffirms "Buy" Rating for Corbus Pharmaceuticals (CRBP)
www.americanbankingnews.com - March 14 at 7:16 PM |
| Insider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) CFO Purchases 3,100 Shares of Stock
www.americanbankingnews.com - March 14 at 1:35 PM |
 | Corbus Wounded in FY17, Shares Sink
www.baystreet.ca - March 13 at 11:45 AM |
| Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
finance.yahoo.com - March 13 at 11:45 AM |
| Corbus Pharmaceuticals (CRBP) Issues Earnings Results
www.americanbankingnews.com - March 13 at 11:12 AM |
| Corbus Pharmaceuticals Holdings Inc (CRBP) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 10 at 9:37 AM |
| Corbus Pharmaceuticals (CRBP) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - March 4 at 8:56 PM |
| Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
finance.yahoo.com - March 2 at 10:27 AM |
| Corbus Pharmaceuticals Holdings Inc (CRBP) Stake Lessened by Raymond James Financial Services Advisors Inc.
www.americanbankingnews.com - March 2 at 8:21 AM |
| What Is Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) Financial Position?
finance.yahoo.com - February 22 at 10:14 AM |
| Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
finance.yahoo.com - February 15 at 3:55 PM |
| Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 14 at 3:21 PM |
| Corbus Pharmaceuticals Holdings Inc (CRBP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 9:22 AM |
| Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
finance.yahoo.com - February 6 at 3:19 PM |
| Corbus Pharmaceuticals (CRBP) Cut to Hold at BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM |
| Corbus Is A Buy, But Not For Cystic Fibrosis - Seeking Alpha
seekingalpha.com - February 2 at 5:43 AM |
| Corbus Pharma awarded $25M from CF Foundation to support development of lenabasum; shares up 3% premarket - Seeking Alpha
seekingalpha.com - February 1 at 3:18 PM |
| Wired News – Cystic Fibrosis Foundation Gets Development Award to Support Corbus Pharma’s Phase-2b Clinical Study of Lenabasum
finance.yahoo.com - February 1 at 3:18 PM |
 | Corbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary ... - StreetInsider.com
www.streetinsider.com - January 31 at 5:49 AM |
| Pre-Open Movers 01/30: (SMRT) (CALD) (CRBP) Higher; (SMG) (MXIMI) (ESRX) (UNH) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 30 at 3:18 PM |
 | Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support ... - Benzinga
www.benzinga.com - January 30 at 3:18 PM |
| Corbus Pharma on go to start mid-stage study of lenabasum in cystic fibrosis; shares up 2% after hours - Seeking Alpha
seekingalpha.com - January 30 at 3:18 PM |
| Corbus Pharma (CRBP) Secures $25M Development Award from ... - StreetInsider.com
www.streetinsider.com - January 30 at 3:18 PM |
| Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
finance.yahoo.com - January 30 at 3:18 PM |
 | Corbus cystic fibrosis drug to get U.S. FDA review on flare-up data
www.nasdaq.com - January 30 at 5:46 AM |
| Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
finance.yahoo.com - January 30 at 5:46 AM |
| Corbus Pharmaceuticals (CRBP) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - January 28 at 9:30 AM |
| 4 Drug Stocks to Watch - Nasdaq
www.nasdaq.com - January 24 at 3:21 PM |
| Analysis: Positioning to Benefit within Ferroglobe, Corbus Pharmaceuticals, Meritage, Dicerna Pharmaceuticals, Castle Brands, and Ply Gem — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - January 24 at 8:31 AM |
| Why the Medical Marijuana Industry Is Growing
finance.yahoo.com - January 22 at 7:56 AM |
| Corbus Pharmaceuticals (CRBP) Coverage Initiated by Analysts at Raymond James Financial
www.americanbankingnews.com - January 20 at 4:08 PM |
| How Marijuana Acceptance Is Evolving Globally
finance.yahoo.com - January 19 at 5:46 PM |
 | Cannabis Market Sales on the Rise According to Data - PR Newswire (press release)
www.prnewswire.com - January 10 at 9:38 AM |
 | BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln
www.reuters.com - January 6 at 9:36 AM |
 | Opinion: Harry Boxer's four stocks popping to start the new year - MarketWatch
www.marketwatch.com - January 5 at 5:01 PM |
| Stock Traders Purchase High Volume of Corbus Pharmaceuticals Call Options (CRBP)
www.americanbankingnews.com - January 4 at 3:36 AM |
| Corbus Pharmaceuticals' (CRBP) Buy Rating Reiterated at Noble Financial
www.americanbankingnews.com - December 30 at 6:14 AM |
| Corbus Pharmaceuticals (CRBP) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - December 29 at 11:56 AM |
| ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 11:28 AM |
| Noble Financial Reaffirms Buy Rating for Corbus Pharmaceuticals (CRBP)
www.americanbankingnews.com - December 25 at 1:32 PM |
| Corbus Pharmaceuticals (CRBP) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 24 at 9:20 AM |
Corbus Pharmaceuticals (NASDAQ:CRBP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Corbus Pharmaceuticals (NASDAQ:CRBP) Income Statement, Balance Sheet and Cash Flow Statement
Corbus Pharmaceuticals (NASDAQ CRBP) Stock Chart for Sunday, April, 22, 2018
Loading chart…
